Metabolic impact of anti-angiogenic agents on U87 glioma cells.

ABSTRACT:

Background

Glioma cells not only secrete high levels of vascular endothelial growth factor (VEGF) but also express VEGF receptors (VEGFR), supporting the existence of an autocrine loop. The direct impact on glioma cells metabolism of drugs targeting the VEGF pathway, such as Bevacizumab (Bev) or VEGFR Tyrosine Kinase Inhibitor (TKI), is poorly known.

Material and methods

U87 cells were treated with Bev or SU1498, a selective VEGFR2 TKI. VEGFR expression was checked with FACS flow cytometry and Quantitative Real-Time PCR. VEGF secretion into the medium was assessed with an ELISA kit. Metabolomic studies on cells were performed using High Resolution Magic Angle Spinning Spectroscopy (HR-MAS).

Results

U87 cells secreted VEGF and expressed low level of VEGFR2, but no dete

SUBMITTER: Mesti T 

PROVIDER: S-EPMC4055646 | biostudies-literature | 2014

REPOSITORIES: biostudies-literature